Summary
Amgen Inc. (AMGN) filed an 8-K report on May 27, 2025, detailing the outcomes of its annual meeting of stockholders held on May 22, 2025. The report primarily covers the election of directors, advisory votes on executive compensation, and the ratification of independent auditors. All 12 director nominees were overwhelmingly elected to serve a one-year term. Additionally, shareholders provided an advisory vote to approve executive compensation, which passed with a significant majority. Furthermore, the company's selection of Ernst & Young LLP as its independent registered public accountants for the fiscal year ending December 31, 2025, was ratified by stockholders. The voting results across all presented proposals indicate strong shareholder support for the company's governance and financial oversight practices. No other business was presented or voted upon during the meeting.
Key Highlights
- 1All 12 director nominees were elected to serve a one-year term until the 2026 annual meeting.
- 2The advisory vote to approve executive compensation received strong majority support from shareholders.
- 3Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year ending December 31, 2025.
- 4Voting outcomes for director elections showed overwhelming support, with 'Votes For' significantly outnumbering 'Votes Against' and 'Abstain' for all nominees.
- 5Broker non-votes were present in the director election and executive compensation vote, a common occurrence in publicly traded companies.
- 6No other business matters were submitted for stockholder action at the meeting.